Pharma’s Voluntary Licensing In India Successful In 2021 – But There Were Some Delicate Moments
Executive Summary
Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.
You may also be interested in...
MSD’s Asia Pacific Chief On Lagevrio’s Gains In Clinical Utility Amid Paxlovid Luster
David Peacock, President, Asia Pacific, MSD tells Scrip how Lagevrio has gained dominance in certain parts of the world, though Paxlovid may have received the ‘lion’s share’ of public attention.
Afrigen MD: WTO IP Waiver Important From ‘Freedom To Operate’ Standpoint
Afrigen’s MD, Petro Terblanche, discusses the operational freedom that the WTO intellectual property waiver provides for its COVID-19 vaccine being developed under the wider WHO-backed mRNA technology transfer hub initiative. The executive doesn’t anticipate big pharma pushback but says the alliance will “test the system”, though others believe the waiver in its current form doesn’t count for much.
South Africa Urged To Revoke Key COVID-19 Patents
Eli Lilly’s Olumiant (baricitinib) patent in South Africa is unjustifiably preventing generics manufacturers from selling cheaper versions of the product in the country, NGO MSF insists. The arthritis drug has been recommended by the WHO as a treatment for severe and critical cases of COVID-19.